The UK and US have secured a landmark trade agreement that will ensure no levies on British drug exports going into the American market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has agreed to boost funding on pharmaceuticals through the National Health Service (NHS). This pledge guarantees that import taxes on these vital goods will be held at zero for a duration of three years.
This development follows previous threats to hike import taxes on patented drug products, with increases discussed up to one hundred percent.
"This agreement with the UK reinforces the international landscape for new treatments and brings long-overdue fairness to transatlantic pharmaceutical trade," an announcement noted.
Trade Importance
Pharmaceuticals constitute one of the UK's biggest export categories to the America, which is by far the largest destination for leading British pharmaceutical firms.
Trade data indicate that in the 12 months to the end of last September, the UK shipped drugs worth billions to the US. This amount represented nearly one-fifth of all goods exports in that period.
"This agreement safeguards jobs, stimulates capital expenditure and facilitates the UK to emerge as a international leader for biotech and pharma," a minister stated.
Detailed UK Commitments
The agreement includes several notable pledges from the British government:
- Price Threshold Increase: The UK will lift the affordability limit at which it considers new treatments to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a target to double overall health service expenditure on treatments from 0.3% of Gross Domestic Product to 0.6% over the coming ten years.
- Payback Limit: The percentage manufacturers must return to the NHS to control costs will be limited at 15%. Last year, refunds topped twenty percent.
Broader Context
The deal follows a protracted row between the drug companies and the UK government over drug pricing and approval rates.
These tensions were exacerbated by claims that US customers were paying significantly more for the same drugs than people in the other developed nations.
Over the last 18 months, several major drug company projects in the UK have been halted or scrapped, while substantial expansions have been announced toward American operations.
One official acknowledged that the NHS must spend more on drugs, noting that its expenditure on drugs had declined as a share of its total funding over the past decade.
